{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T13:36:54Z","timestamp":1648993014885},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,6]],"date-time":"2014-09-06T00:00:00Z","timestamp":1409961600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1752-1947-8-295","type":"journal-article","created":{"date-parts":[[2014,9,6]],"date-time":"2014-09-06T09:01:04Z","timestamp":1409994064000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report"],"prefix":"10.1186","volume":"8","author":[{"given":"Giovanni","family":"Caocci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"La Nasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,6]]},"reference":[{"key":"2917_CR1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini A, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, M\u00fcller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Sau\u03b2ele S, Schiffer C, Silver R, Simonsson B, Steegmann JL: European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood. 2013, 122: 872-884. 10.1182\/blood-2013-05-501569.","journal-title":"Blood"},{"key":"2917_CR2","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P, Intergroupe Fran\u00e7ais des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques: Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010, 11: 1029-1035. 10.1016\/S1470-2045(10)70233-3.","journal-title":"Lancet Oncol"},{"key":"2917_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP: Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER Study. Blood. 2013, 122: 515-522. 10.1182\/blood-2013-02-483750.","journal-title":"Blood"},{"key":"2917_CR4","doi-asserted-by":"crossref","unstructured":"Benjamini O, Kantarjian H, Rios MB, Jabbour E, O\u2019Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes J: Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma in press. doi:10.3109\/10428194.2013.831092","DOI":"10.3109\/10428194.2013.831092"},{"issue":"21 ASH Annual M","key":"2917_CR5","doi-asserted-by":"crossref","first-page":"Abstract 916","DOI":"10.1182\/blood.V120.21.916.916","volume":"120","author":"D Rea","year":"2012","unstructured":"Rea D, Rousselot P, Guilhot F, Tulliez M, Nicolini FE, Guerci-Bresler A, Legros L, Gardembas M, Giraudier S, Guillerm G, Mahon FX: Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts [abstract]. Blood. 2012, 120 (21 ASH Annual Meeting Abstracts issue): Abstract 916-","journal-title":"Blood"},{"issue":"21 ASH Annual M","key":"2917_CR6","first-page":"Abstract 3998","volume":"122","author":"H Tanaka","year":"2013","unstructured":"Tanaka H, Imagawa J, Okada M, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Morita S, Sakamoto J, Kimura S: Discontinuation of dasatinib in patients with CML who have maintained complete molecular response for at least one year: results from a prospective discontinuation (DADI) trial [abstract]. Am Soc Hematol. 2013, 122 (21 ASH Annual Meeting Abstracts issue): Abstract 3998-","journal-title":"Am Soc Hematol"},{"key":"2917_CR7","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3324\/haematol.2011.048165","volume":"96","author":"DM Ross","year":"2011","unstructured":"Ross DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP: Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features. Haematologica. 2011, 96: 1720-1722. 10.3324\/haematol.2011.048165.","journal-title":"Haematologica"},{"key":"2917_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/2162-3619-1-17","volume":"1","author":"K Gad\u00f3","year":"2012","unstructured":"Gad\u00f3 K, Matolcsy A, Csomor J, Kicsi D, B\u00f6d\u00f6r C, Domj\u00e1n G: Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia. Exp Hematol Oncol. 2012, 1: 17-10.1186\/2162-3619-1-17.","journal-title":"Exp Hematol Oncol"},{"key":"2917_CR9","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3109\/10428194.2011.649753","volume":"53","author":"J Aoki","year":"2012","unstructured":"Aoki J, Ohashi K, Kobayashi T, Kakihana K, Hirashima Y, Sakamaki H: Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors. Leuk Lymphoma. 2012, 53: 1412-1414. 10.3109\/10428194.2011.649753.","journal-title":"Leuk Lymphoma"},{"key":"2917_CR10","first-page":"17","volume":"12","author":"M Breccia","year":"2013","unstructured":"Breccia M, Alimena G, Baccarani M, Bocchia M, Di Raimondo F, Gambacorti-Passerini C, Gozzini A, Morra E, Pane F, Pregno P, Rege-Cambrin G, Rosti G, Specchia G, Vigneri P, Saglio G: Current management of CML patients: summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013. Crit Rev Oncol Hematol. 2013, 12: 17-","journal-title":"Crit Rev Oncol Hematol"},{"key":"2917_CR11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.exphem.2013.01.008","volume":"41","author":"G La Nasa","year":"2013","unstructured":"La Nasa G, Caocci G, Littera R, Atzeni S, Vacca A, Mulas O, Langiu M, Greco M, Orr\u00f9 S, Orr\u00f9 N, Floris A, Carcassi C: Homozygosity for killer immunoglobulin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients. Exp Hematol. 2013, 41: 424-431. 10.1016\/j.exphem.2013.01.008.","journal-title":"Exp Hematol"},{"key":"2917_CR12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3324\/haematol.2011.056853","volume":"97","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, Usui N, Okamoto S, Ohe Y, Ohtake S, Kitamura K, Yamamoto M, Teshima H, Motoji T, Tamaki T, Sawada K, Ohyashiki K: Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012, 97: 903-906. 10.3324\/haematol.2011.056853.","journal-title":"Haematologica"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-8-295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1752-1947-8-295\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-8-295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-8-295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T04:06:04Z","timestamp":1598241964000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/1752-1947-8-295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,6]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2917"],"URL":"https:\/\/doi.org\/10.1186\/1752-1947-8-295","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,6]]},"assertion":[{"value":"20 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"295"}}